<DOC>
	<DOCNO>NCT02202473</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Oxymatrine plus Lamivudine Combination Therapy whether could lower incidence Lamivudine long-term resistance compare Lamivudine Monotherapy .</brief_summary>
	<brief_title>Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy Chronic Hepatitis B Infected Subjects</brief_title>
	<detailed_description>Group A ( Lamivudine Monotherapy ) : Lamivudine ( Manufacturer : GlaxoSmithKline ) 100mg po , qd . Group B ( Oxymatrine + Lamivudine Combination Therapy ) : Lamivudine ( Manufacturer : GlaxoSmithKline ) 100mg po , qd ; oxymatrine Capsules ( Chia Tai Tianqing Pharmaceutical Group Co. , Ltd ) 200 mg , po , tid . Total subject : 200 , 100 patient randomize group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Oxymatrine</mesh_term>
	<criteria>1 . 18 60 year old . 2 . Subjects diagnose chronic hepatitis B accord 2000 Xi'an Conference Guidelines : Management chronic hepatitis B. Alanine transaminase &gt; 80 IU/L , total bilirubin &lt; 85.5 mmol/L , Hepatitis B virus DNA &gt; 1×10^5copies/mL ; n't treat antiviral therapy within 6 month screen . 3. able give write informed consent comply study protocol . 4 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study . 1 . Evidence hepatocellular carcinoma 2 . Clinical symptom Decompensated liver disease screening , include limited : Serum bilirubin≥1.5 x upper limit normal , prothrombin time great 2 second prolonged , serum albumin &lt; 32g/L , history ascites , variceal bleeding , hepatic encephalopathy ; 3 . Alanine transaminase &gt; 10 x upper limit normal screen history Transient hepatic decompensation cause acute exacerbation ; 4. hemoglobin &lt; 10g/dL , Neutrophil count &lt; 1.5 × 10^9/L , platelet count &lt; 80 × 10^9/L ; 5 . Evidence active liver disease cause , include coinfection hepatitis A virus , coinfection hepatitis E virus , coinfection hepatitis C virus , coinfection hepatitis D virus , coinfection HIV , autoimmune hepatitis ( antinuclear antibody titer &gt; 1:100 ) ; 6 . Use immunosuppressor , immunomodulators ( include interferon thymosin ) within 6 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Oxymatrine Capsules , lamivudine , chronic Hepatitis B</keyword>
</DOC>